Abstract:Background Cytokine release syndrome (CRS) is a potentially life-threatening complication of chimeric antigen receptor T (CAR-T) cell therapy. Recent studies indicated critical roles of macrophages and monocytes in CAR-T induced CRS. Here, we report rapid dissipation of CAR-T induced CRS in two patients after receiving Tripterygium glycosides (TG). Effects of triptolide, the major active component of TG, on macrophages and monocytes were examined in animal models. Methods Two patients with CRS after CAR-T cell therapy (for hematological malignancy) received TG (50 mg, p.o.). Flow cytometry analysis and single cell RNA sequencing (scRNAseq) were conducted to examine the effects of TG on immune cells. Potential effects of triptolide were also examined ex vivo using patient-derived monocytes, as well as in mice. Findings Rapid alleviation of fever and cytokine storm was observed within 72 hours after TG treatment. Blood concentration of triptolide ranged from 21 to 154 ng/mL during treatment. Flow cytometry and scRNAseq showed selective depletion of monocytes with minimal impact on CAR-T cells in both patients. In ex vivo experiments with patient-derived monocytes, triptolide dramatically inhibited the synthesis of pro-inflammatory cytokines (e.g., IL-6, IL-10, and IP-10). Triptolide also rapidly and selectively depleted peritoneal concanavalin A activated macrophages and monocytes in mice. Interpretation TG could be a promising treatment for CAR-T induced CRS, as well as other diseases with similar mechanisms, e.g., hemophagocytic lymphohistiocytosis and COVID-19. Our preliminary findings require further verification with properly designed clinical trials. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial ChiCTR-OIC-17013081,ChiCTR1900028098,ChiCTROIC-17011272 ### Funding Statement This study was supported in part by the Science and Technology Development Program of Jiangsu Province-Clinical Frontier Technology (grant Nos. BE2016809, BE2017639), the Nanjing Science and Technology Development Program (grant Nos. 201503011), the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD) (grant Nos. 035062002003c), and the development program of Jiangsu Provincial Hospital of Chinese Medicine (grant Nos.Y19030, Y19066). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This research has been approved by Institutional Review Board of Affiliate Hospital of Nanjing University of Chinese Medicine. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes All data are available upon request by emailing to zhuxuejun{at}njucm.edu.cn.

CAR-T cell-induced cytokine release syndrome is rapidly alleviated by tripterygium glycosides

Tripterygium glycosides as a potential treatment for CAR-T induced cytokine release syndrome: implication of monocyte depletion

Cytokine Release Syndrome in Cancer Immunotherapy with Chimeric Antigen Receptor Engineered T Cells.

Glycyrrhizin for treatment of CRS caused by CAR T-cell therapy: A pharmacological perspective

Management of Cytokine Release Syndrome Related to CAR-T Cell Therapy

Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy

Predictive Role of Endothelial Cell Activation in Cytokine Release Syndrome after Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukaemia

Self-regulating CAR-T cells modulate cytokine release syndrome in adoptive T-cell therapy

Suppression of cytokine release syndrome during CAR-T-cell therapy via a subcutaneously injected interleukin-6-adsorbing hydrogel

Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment

Abnormal Coagulation Function In Chimeric Antigen Receptor T Cell Treatment Of Hematologic Malignancies

Coagulation Disorders after Chimeric Antigen Receptor T Cell Therapy: Analysis of 100 Patients with Relapsed and Refractory Hematologic Malignancies

Macrophage, the potential key mediator in CAR-T related CRS

Early induction of cytokine release syndrome by rapidly generated CAR T cells in preclinical models

CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade

Multi-centers experience using therapeutic plasma exchange for corticosteroid/tocilizumab-refractory cytokine release syndrome following CAR-T therapy

Using Jak Inhibitor To Treat Cytokine Release Syndrome Developed After Chimeric Antigen Receptor T Cell Therapy For Patients With Refractory Acute Lymphoblastic Leukemia A Case Report

Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome

Correlation of Cytokine Release Syndrome With Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients With Relapsed or Refractory Multiple Myeloma

Plasma exchange can be an alternative therapeutic modality for severe cytokine release syndrome after chimeric antigen receptor-T cell infusion: a case report.

Neutrophil Activation and Clonal CAR-T Re-Expansion Underpinning Cytokine Release Syndrome During Ciltacabtagene Autoleucel Therapy in Multiple Myeloma